# Bacillus licheniformis ATCC 14580

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/bacillus-licheniformis-atcc-14580
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-25
**Evidence Score:** 2 / 10
**Category:** Fermented/Probiotic
**Also Known As:** Bacillus licheniformis strain ATCC 14580, B. licheniformis ATCC 14580, ATCC 14580, Bacillus licheniformis type strain, B. licheniformis reference strain, Soil bacillus ATCC 14580

## Overview

Bacillus licheniformis ATCC 14580 is a gram-positive, spore-forming bacterium whose primary bioactive outputs include bacteriocins and hydrolytic enzymes such as subtilisin-like proteases, which disrupt microbial cell membranes in vitro. Current evidence is restricted to genomic characterization and industrial fermentation contexts, with no documented human clinical trials evaluating its use as a [probiotic](/ingredients/condition/gut-health) supplement.

## Health Benefits

• No human clinical evidence available - current research focuses solely on genomic comparisons and industrial applications
• Demonstrated antibacterial activity against E. coli and S. aureus in laboratory studies (non-human data)
• Potential rumen modulation effects observed in animal studies only
• Spore-forming nature suggests theoretical resilience during GI transit (no human studies)
• Industrial enzyme production capabilities documented but no human health outcomes studied

## Mechanism of Action

Bacillus licheniformis ATCC 14580 produces bacteriocins and subtilisin-like serine proteases that degrade outer membrane proteins of gram-negative bacteria such as E. coli, disrupting membrane integrity and inhibiting cell replication. Its genome encodes biosynthetic gene clusters for iturin-related lipopeptides, which intercalate into microbial phospholipid bilayers, inducing ion leakage and cell death. In ruminant-focused animal models, metabolite secretion is hypothesized to modulate volatile fatty acid ratios in the rumen [microbiome](/ingredients/condition/gut-health), though the precise enzymatic cascade responsible has not been isolated in controlled trials.

## Clinical Summary

No human clinical trials have been conducted specifically using Bacillus licheniformis ATCC 14580 as a dietary supplement or [probiotic](/ingredients/condition/gut-health) intervention. In vitro studies have demonstrated minimum inhibitory concentrations (MICs) against E. coli and Staphylococcus aureus, but these results were obtained under controlled laboratory conditions that do not replicate human gastrointestinal physiology. Animal studies in ruminants suggest potential modulation of rumen fermentation parameters, though sample sizes are small and endpoints are not translatable to human health outcomes. The overall evidence base is rated very low quality for any human health claim, and regulatory bodies have not evaluated this specific strain for probiotic efficacy.

## Nutritional Profile

Bacillus licheniformis ATCC 14580 is a bacterial strain consumed as a [probiotic](/ingredients/condition/gut-health)/fermentation agent, not a conventional food ingredient with macronutrient value. As a spore-forming gram-positive bacterium, its nutritional contribution when ingested is negligible in terms of macronutrients (protein, fat, carbohydrate content derived from bacterial biomass is trace-level at typical probiotic doses of 1×10^6 to 1×10^9 CFU). Bioactive compounds of documented relevance include: licheniformin (a cyclic peptide bacteriocin with antimicrobial properties), bacitracin precursor peptides (produced via non-ribosomal peptide synthetases encoded in the ATCC 14580 genome, confirmed via genomic sequencing published 2004), and subtilisin-like serine proteases (biosynthetically active extracellular enzymes). The strain produces gamma-polyglutamic acid (γ-PGA) at laboratory scale, a bioactive polymer with reported mineral-chelating properties. Cell wall components include peptidoglycan (muramic acid backbone) and teichoic acids, which may act as [immunomodulatory](/ingredients/condition/immune-support) ligands (TLR2 agonists) at mucosal surfaces. Endospore coat proteins (CotA laccase confirmed genomically) are present. No clinically measured micronutrient delivery data exists for this specific strain. Bioavailability note: as a spore-former, viable spores may survive gastric acid (pH 2–3) and germinate in the intestinal environment, making bioactive compound exposure site-specific to the lower GI tract rather than systemic absorption.

## Dosage & Preparation

No clinically studied dosage ranges are available for Bacillus licheniformis ATCC 14580 in humans. No standardization protocols (CFU counts), forms (powder, capsules), or human dosing guidelines have been established. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Because no human clinical trials exist for ATCC 14580 specifically, its safety profile in humans is formally unestablished and cannot be extrapolated from related Bacillus licheniformis strains without direct evidence. Bacillus licheniformis species broadly are considered opportunistic pathogens in immunocompromised individuals, raising theoretical concern for bacteremia or septicemia with live-spore oral supplementation. No documented drug interaction data exist for this strain; however, co-administration with immunosuppressants or broad-spectrum antibiotics warrants caution given its bacteriocin-producing properties. Pregnant and breastfeeding individuals should avoid this strain entirely due to the complete absence of safety data in these populations.

## Scientific Research

No human clinical trials, RCTs, or meta-analyses exist for Bacillus licheniformis ATCC 14580 as a clinical [probiotic](/ingredients/condition/gut-health). Current studies focus exclusively on genomic comparisons, rumen-derived strains, and industrial enzyme production applications without any PubMed-indexed human health outcome data.

## Historical & Cultural Context

No historical or traditional medicine use is documented for Bacillus licheniformis ATCC 14580 in any traditional systems including Ayurveda or TCM. Its applications are entirely modern, limited to agricultural [probiotic](/ingredients/condition/gut-health)s, microbial fertilizers, and industrial enzyme production.

## Synergistic Combinations

Other Bacillus strains, soil-based organisms, industrial [probiotic](/ingredients/condition/gut-health)s, agricultural probiotics

## Frequently Asked Questions

### Is Bacillus licheniformis ATCC 14580 safe for human consumption?

There are no published human safety studies for Bacillus licheniformis ATCC 14580 specifically. The broader Bacillus licheniformis species is classified as a potential opportunistic pathogen, particularly in immunocompromised individuals, meaning consumption of live spores carries theoretical infection risk. No regulatory agency has granted this specific strain GRAS (Generally Recognized as Safe) status for use in dietary supplements.

### What bacteria does Bacillus licheniformis ATCC 14580 kill?

In vitro laboratory studies have shown antibacterial activity against Escherichia coli and Staphylococcus aureus, mediated primarily through bacteriocin and subtilisin-like protease secretion that degrades cell membranes. These results were obtained in controlled culture conditions and have not been replicated in animal or human gastrointestinal models. The clinical relevance of these in vitro MIC values to real-world infection control is therefore unknown.

### What is Bacillus licheniformis ATCC 14580 used for industrially?

This strain is extensively studied for industrial biotechnology applications, including the production of subtilisin proteases used in detergent formulations, as well as thermostable amylases and lipopeptide biosurfactants. Its fully sequenced genome (GenBank accession AE017333) has made it a reference strain for comparative genomics in Bacillus research. Industrial use is entirely distinct from probiotic or human health supplementation contexts.

### Does Bacillus licheniformis ATCC 14580 have probiotic effects in animals?

Preliminary animal research, primarily in ruminants such as cattle, suggests that Bacillus licheniformis strains may alter rumen microbial composition and influence volatile fatty acid production, which affects feed efficiency. However, studies using the specific ATCC 14580 strain are limited, and results have not been statistically robust enough to establish dosage or efficacy thresholds. These findings cannot be directly applied to monogastric animals or humans without dedicated trials.

### How does Bacillus licheniformis ATCC 14580 differ from probiotic Bacillus strains in supplements?

Commercially used probiotic Bacillus strains such as Bacillus subtilis DE111 or Bacillus coagulans GBI-30 have undergone randomized controlled human trials demonstrating safety and specific gastrointestinal outcomes at defined dosages. ATCC 14580 has not been evaluated in any human clinical setting and its primary research context remains industrial enzyme production and genomic reference work. The absence of strain-specific human data means it does not meet the evidentiary standards required for evidence-based probiotic classification.

### What does clinical research show about Bacillus licheniformis ATCC 14580 in humans?

Currently, no human clinical trials have been published for Bacillus licheniformis ATCC 14580 as a probiotic supplement. Existing research is limited to in vitro laboratory studies demonstrating antibacterial activity against pathogens like E. coli and S. aureus, and animal studies showing potential rumen modulation effects in livestock. Before considering this strain for human use, clinical evidence in human subjects would be needed to establish efficacy and appropriate dosing.

### Who should avoid Bacillus licheniformis ATCC 14580 supplements?

Individuals with severe immunocompromise, invasive medical devices, or a history of Bacillus-related infections should consult a healthcare provider before use, as spore-forming bacteria may pose theoretical risks in these populations. Pregnant women and children should also seek professional medical guidance, as no human safety data exists for these groups. Anyone with known allergies to Bacillus species or experiencing acute gastrointestinal illness should avoid this supplement until symptoms resolve.

### How is Bacillus licheniformis ATCC 14580 different from other Bacillus probiotics used in supplements?

Bacillus licheniformis ATCC 14580 is a specific laboratory strain (ATCC catalog number indicates standardized culture collection origin) primarily characterized through genomic and industrial enzyme production studies rather than human probiotic efficacy trials. While other Bacillus strains like B. subtilis and B. clausii have some animal or preliminary human research, ATCC 14580 lacks comparable clinical validation for probiotic claims. The distinction is important because this strain's use is largely based on theoretical properties and industrial applications rather than demonstrated human health benefits.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*